Preventing and managing toxicities of high-dose methotrexate
SC Howard, J McCormick, CH Pui… - The …, 2016 - academic.oup.com
Abstract High-dose methotrexate (HDMTX), defined as a dose higher than 500 mg/m2, is
used to treat a range of adult and childhood cancers. Although HDMTX is safely …
used to treat a range of adult and childhood cancers. Although HDMTX is safely …
[HTML][HTML] Childhood acute lymphoblastic leukemia: progress through collaboration
CH Pui, JJ Yang, SP Hunger, R Pieters… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
Purpose To review the impact of collaborative studies on advances in the biology and
treatment of acute lymphoblastic leukemia (ALL) in children and adolescents. Methods A …
treatment of acute lymphoblastic leukemia (ALL) in children and adolescents. Methods A …
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal …
RM Cooper‐DeHoff, M Niemi… - Clinical …, 2022 - Wiley Online Library
Statins reduce cholesterol, prevent cardiovascular disease, and are among the most
commonly prescribed medications in the world. Statin‐associated musculoskeletal …
commonly prescribed medications in the world. Statin‐associated musculoskeletal …
[HTML][HTML] Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations
Maintenance therapy (MT) with oral methotrexate (MTX) and 6-mercaptopurine (6-MP) is
essential for the cure of acute lymphoblastic leukemia (ALL). MTX and 6-MP interfere with …
essential for the cure of acute lymphoblastic leukemia (ALL). MTX and 6-MP interfere with …
Acute lymphoblastic leukaemia
H Inaba, M Greaves, CG Mullighan - The Lancet, 2013 - thelancet.com
Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks
between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous …
between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous …
[HTML][HTML] The genetic landscape of major drug metabolizing cytochrome P450 genes—an updated analysis of population-scale sequencing data
Y Zhou, VM Lauschke - The Pharmacogenomics Journal, 2022 - nature.com
Genes encoding cytochrome P450 enzymes (CYPs) are extremely polymorphic and multiple
CYP variants constitute clinically relevant biomarkers for the guidance of drug selection and …
CYP variants constitute clinically relevant biomarkers for the guidance of drug selection and …
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update
LB Ramsey, SG Johnson, KE Caudle… - Clinical …, 2014 - Wiley Online Library
Simvastatin is among the most commonly used prescription medications for cholesterol
reduction. A single coding single‐nucleotide polymorphism, rs4149056T> C, in SLCO1B1 …
reduction. A single coding single‐nucleotide polymorphism, rs4149056T> C, in SLCO1B1 …
Pharmacogenetics at scale: an analysis of the UK Biobank
Pharmacogenetics (PGx) studies the influence of genetic variation on drug response.
Clinically actionable associations inform guidelines created by the Clinical …
Clinically actionable associations inform guidelines created by the Clinical …
Bringing genome-wide association findings into clinical use
TA Manolio - Nature Reviews Genetics, 2013 - nature.com
Genome-wide association studies (GWASs) have been heralded as a major advance in
biomedical discovery, having identified~ 2,000 robust associations with complex diseases …
biomedical discovery, having identified~ 2,000 robust associations with complex diseases …
Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature
ATP-binding cassette transporter B1 (ABCB1; P-glycoprotein; multidrug resistance protein 1)
is an adenosine triphosphate (ATP)-dependent efflux transporter located in the plasma …
is an adenosine triphosphate (ATP)-dependent efflux transporter located in the plasma …